Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize ...

While the initial HexaBody-CD38 clinical data is promising and showed ... next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is ...

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

Longevity research has propelled the scientific community to concentrate on interventions that do more than simply add years to life ...

It is thought that CD38-expressing cells contribute to disease ... in the kidneys and cause inflammation and loss of kidney function. Felzartamab's mode of action is to deplete those antibody ...

Connamara Technologies, a leading provider of exchange technology, announced that co-founder and chair Maureen C. Downs was honored with the "Trailblazer Lifetime Achievement Award (vendor)" by ...

Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...

The Research Topic ‘Adenine Nucleotides in Immunity and Inflammation’ comprises reviews discussing the current state of the field, in addition to original research articles that clarify specific ...

Cell clustering implemented FindNeighbors and FindClusters functions. The UMAP method facilitated cell ... BCL6, CSDC2, C1orf105, CD38, FAM46B, AREG, FAM83B, ANPEP, MT1A, METTL7B) (Figure 3). These ...